Deutsche Bank Ag\ Cyclerion Therapeutics, Inc. Transaction History

Deutsche Bank Ag\

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 04, 2021	SELL	$2.73 - $4.13 $179,907 - $272,167	-65,900 Closed	0 $0
Q2 2021 Aug 11, 2021	SELL	$2.18 - $4.29 $33,088 - $65,113	-15,178 Reduced 18.72%	65,900 $257,000
Q1 2021 May 13, 2021	BUY	$2.69 - $5.12 $175,799 - $334,607	65,353 Added 415.6%	81,078 $226,000
Q4 2020 Feb 16, 2021	BUY	$2.25 - $7.12 $8,676 - $27,454	3,856 Added 32.49%	15,725 $48,000
Q3 2020 Nov 12, 2020	BUY	$3.46 - $8.39 $3,716 - $9,010	1,074 Added 9.95%	11,869 $72,000
Q2 2020 Aug 13, 2020	BUY	$2.37 - $7.14 $5,640 - $16,993	2,380 Added 28.28%	10,795 $64,000
Q1 2020 May 14, 2020	SELL	$2.46 - $5.84 $1,313 - $3,118	-534 Reduced 5.97%	8,415 $23,000
Q4 2019 Feb 14, 2020	BUY	$1.8 - $13.43 $3,101 - $23,139	1,723 Added 23.84%	8,949 $23,000
Q3 2019 Nov 14, 2019	SELL	$8.12 - $14.54 $89,100 - $159,547	-10,973 Reduced 60.29%	7,226 $87,000
Q2 2019 Aug 14, 2019	BUY	$9.6 - $22.85 $174,710 - $415,847	18,199 New	18,199 $207,000

293K

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $97M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.